HRP20231160T1 - Solubilizat s kurkuminom, bosvelijom i ksantohumolom - Google Patents

Solubilizat s kurkuminom, bosvelijom i ksantohumolom Download PDF

Info

Publication number
HRP20231160T1
HRP20231160T1 HRP20231160TT HRP20231160T HRP20231160T1 HR P20231160 T1 HRP20231160 T1 HR P20231160T1 HR P20231160T T HRP20231160T T HR P20231160TT HR P20231160 T HRP20231160 T HR P20231160T HR P20231160 T1 HRP20231160 T1 HR P20231160T1
Authority
HR
Croatia
Prior art keywords
range
temperature
polysorbate
mass
solubilizate
Prior art date
Application number
HRP20231160TT
Other languages
English (en)
Inventor
Dariush Behnam
Original Assignee
Aquanova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/067382 external-priority patent/WO2019011415A1/de
Priority claimed from PCT/EP2017/067381 external-priority patent/WO2019011414A1/de
Priority claimed from DE102017115496.5A external-priority patent/DE102017115496A1/de
Application filed by Aquanova Ag filed Critical Aquanova Ag
Publication of HRP20231160T1 publication Critical patent/HRP20231160T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)

Claims (13)

1. Solubilizat koji se pretežno sastoji od kurkumina u sadržaju od 10 % masenog udjela ili manje, poželjno 8 % masenog udjela ili manje, najpoželjnije od 3 % masenog udjela do 7 % masenog udjela; jedne ili više bosveličnih kiselina i/ili jednog ili više derivata bosvelične kiseline, posebice 11 keto-β-bosvelična kiselina, KBA, (CAS 17019-92-0), 3-O-acetil-11-keto-β-bosvelična kiselina, AKBA, (CAS 67416-16-9), 3-O-acetil-α-bosvelična kiselina, AaBA, i/ili 3-O-acetil-β-bosvelična kiselina, AβBA, u ukupnom sadržaju od 10 % masenog udjela ili manje, poželjno 8 % masenog udjela ili manje, najpoželjnije od 3 % masenog udjela do 6,6 % masenog udjela; i ksantohumola u sadržaju od 10 % masenog udjela ili manje, poželjno 5 % masenog udjela ili manje, najpoželjnije od 1 % masenog udjela do 3 % masenog udjela; i najmanje jednog emulgatora, odnosno polisorbata 80 ili polisorbata 20 ili smjese polisorbata 20 i polisorbata 80; naznačeno time da sadržaj emulgatora, posebice sadržaj polisorbata, iznosi najmanje 70 % masenog udjela, poželjno između 75 % masenog udjela i 95 % masenog udjela, najpoželjnije između 79 % masenog udjela i 88 % masenog udjela.
2. Solubilizat prema zahtjevu 1, naznačeno time da solubilizat sadrži ekstrakt iz smole biljke boswellia serrata dobivene ekstrakcijom etil acetatom, kao izvor za jednu ili više bosveličnih kiselina i/ili jednog ili više derivata bosvelične kiseline, pri čemu taj ekstrakt sadrži bosvelične kiseline u koncentraciji od najmanje 85 % masenog udjela.
3. Solubilizat prema bilo kojem od prethodnih zahtjeva, naznačeno time da je omjer emulgatora i bosveličnih kiselina i/ili bosveličnih kiselina i najmanje jednog od njezinih derivata u rasponu između 20 : 1 i 3 : 1, poželjno u rasponu između 16 : 1 i 4 : 1, poželjno u rasponu između 14 : 1 i 5 : 1, i/ili time da je omjer emulgatora i kurkumina u rasponu između 30 : 1 i 3 : 1, poželjno u rasponu između 25 : 1 i 9 : 1, poželjno u rasponu između 23 : 1 i 12 : 1, i/ili time da je omjer emulgatora, posebice polisorbata 80, i ksantohumola u rasponu između 30 : 1 i 3 : 1, poželjno u rasponu između 25 : 1 i 5 : 1, poželjno u rasponu između 9,8 : 1 i 6,6 : 1, i/ili time da solubilizat sadrži do 20 % masenog udjela, poželjno do 15 % masenog udjela etanola, i/ili time da je raspodjela promjera micela u otopini solubilizata i destilirane vode u omjeru 1 : 500 pri pH 1,1 i 37 °C u rasponu od približno d10 = 6 nm do približno d90 = 16 nm, i/ili time da je solubilizat zamućen manje od 25 FNU, poželjno manje od 3 FNU, mjereno raspršenim infracrvenim svjetlom u skladu sa specifikacijama norme ISO 7027 tako da je solubilizat razrijeđen u omjeru 1 : 50 u vodi u fiziološkim uvjetima (pH 1,1 i 37 °C).
4. Solubilizat prema bilo kojem od prethodnih zahtjeva, naznačeno time da solubilizat sadrži ksantohumol u neotopljenom obliku, posebice u prirodnom obliku.
5. Kapsula napunjena solubilizatom prema bilo kojem od prethodnih zahtjeva, naznačeno time da je kapsula u obliku meke želatinske kapsule ili tvrde želatinske kapsule ili meke kapsule bez želatine ili tvrde kapsule bez želatine, primjerice celulozna kapsula.
6. Tekućina koja sadrži solubilizat prema bilo kojem od zahtjeva 1 do 4, naznačeno time da je tekućina odabrana iz skupine koja obuhvaća hranu, dodatke prehrani, pića, kozmetiku i farmaceutske proizvode.
7. Tekućina prema zahtjevu 6, naznačeno time da tekućina sadrži vodenu otopinu solubilizata.
8. Solubilizat prema bilo kojem od zahtjeva 1 do 4 ili tekućina prema bilo kojem od zahtjeva 6 ili 7 posebice za oralnu upotrebu kao dodatak prehrani i/ili kao farmaceutski lijek u postupku za liječenje i/ili prevenciju bolesti kao što su upale, rak, Alzheimerova bolest, Parkinsonova bolest, pretilost, visok kolesterol, visoka razina šećera u krvi, metabolički sindrom i/ili autoimune bolesti.
9. Solubilizat za upotrebu prema zahtjevu 8 kao dodatak prehrani i/ili kao farmaceutski lijek u dozi kurkumina u rasponu od 0,5 mg/kg tjelesne težine do 1 mg/kg tjelesne težine, poželjno u dozi od 0,81 mg/kg tjelesne težine; i u dozi bosvelije u rasponu od 1 mg/kg tjelesne težine do 2 mg/kg tjelesne težine, poželjno u dozi od 1,62 mg/kg tjelesne težine; i u dozi ksantohumola u rasponu od 0,5 mg/kg tjelesne težine do 1 mg/kg tjelesne težine, poželjno u dozi od 0,81 mg/kg tjelesne težine, posebice jednom dnevno.
10. Postupak za proizvodnju solubilizata prema bilo kojem od zahtjeva 1 do 4, koji uključuje sljedeće korake: (a) osiguravanje polisorbata 80 i/ili polisorbata 20 i/ili smjese polisorbata 20 i polisorbata 80; (b) dodavanje praha ekstrakta biljke boswellia serrata i etanolnog ekstrakta tvrdih smola iz hmelja, (c) dodavanje kurkumina u prahu; pri čemu korak (a) uključuje zagrijavanje do temperature u rasponu od 40 °C do 62 °C, poželjno do temperature u rasponu od 45 °C do 57 °C, najpoželjnije do temperature u rasponu od 48 °C do 52 °C; i pri čemu korak (b) uključuje zagrijavanje do temperature u rasponu od 60 °C do 75 °C, poželjno do temperature u rasponu od 61 °C do 70 °C, najpoželjnije do temperature u rasponu od 63 °C do 67 °C. i pri čemu korak (c) uključuje zagrijavanje do temperature u rasponu od 82 °C do 97 °C, poželjno do temperature u rasponu od 83 °C do 92 °C, najpoželjnije do temperature u rasponu od 85 °C do 89 °C.
11. Postupak za proizvodnju solubilizata prema bilo kojem od zahtjeva 1 do 4, koji uključuje sljedeće korake: (a) osiguravanje polisorbata 80 i/ili polisorbata 20 i/ili smjese polisorbata 20 i polisorbata 80; (b) dodavanje praha ekstrakta biljke boswellia serrata; (c) dodavanje kurkumina u prahu; pri čemu korak (a) uključuje zagrijavanje do temperature u rasponu od 40 °C do 62 °C, poželjno do temperature u rasponu od 45 °C do 57 °C, najpoželjnije do temperature u rasponu od 48 °C do 52 °C; i pri čemu korak (b) uključuje zagrijavanje do temperature u rasponu od 60 °C do 75 °C, poželjno do temperature u rasponu od 61 °C do 70 °C, najpoželjnije do temperature u rasponu od 63 °C do 67 °C. i pri čemu korak (c) uključuje zagrijavanje do temperature u rasponu od 82 °C do 97 °C, poželjno do temperature u rasponu od 83 °C do 92 °C, najpoželjnije do temperature u rasponu od 85 °C do 89 °C i koji sadrži sljedeći korak: d) dodavanje etanolnog ekstrakta tvrdih smola iz hmelja na temperaturi u rasponu od 26 °C do 30 °C.
12. Postupak prema zahtjevu 10 ili 11, pri čemu se prije koraka (b) provodi korak (b1), koji uključuje dodavanje vode pri temperaturi u rasponu od 40 °C do 62 °C, poželjno pri temperaturi u rasponu od 45 °C do 57 °C, najpoželjnije pri temperaturi u rasponu od 48 °C do 52 °C.
13. Postupak za proizvodnju solubilizata prema bilo kojem od zahtjeva 1 do 4, koji uključuje miješanje solubilizata kurkumina i solubilizata bosvelije i solubilizata ksantohumola, posebice u kvantitativnom omjeru 1 : 1 : 1.
HRP20231160TT 2017-07-11 2018-07-11 Solubilizat s kurkuminom, bosvelijom i ksantohumolom HRP20231160T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2017/067382 WO2019011415A1 (de) 2017-07-11 2017-07-11 SOLUBILISAT MIT CURCUMIN, XANTHOHUMOL UND SÜßHOLZWURZELEXTRAKT
PCT/EP2017/067381 WO2019011414A1 (de) 2017-07-11 2017-07-11 Solubilisat mit curcumin und boswellia
DE102017115496.5A DE102017115496A1 (de) 2017-07-11 2017-07-11 Süßholzwurzelextrakt-Solubilisat
PCT/EP2018/068729 WO2019011954A1 (de) 2017-07-11 2018-07-11 Solubilisat mit curcumin und boswellia und xanthohumol
EP18737623.1A EP3651804B1 (de) 2017-07-11 2018-07-11 Solubilisat mit curcumin und boswellia und xanthohumol

Publications (1)

Publication Number Publication Date
HRP20231160T1 true HRP20231160T1 (hr) 2024-01-05

Family

ID=62837944

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20231591TT HRP20231591T1 (hr) 2017-07-11 2018-07-11 Solubilizat s kurkuminom i barem jednom drugom aktivnom tvari
HRP20231160TT HRP20231160T1 (hr) 2017-07-11 2018-07-11 Solubilizat s kurkuminom, bosvelijom i ksantohumolom
HRP20231135TT HRP20231135T1 (hr) 2017-07-11 2019-07-10 Solubilizat s kurkuminom i najmanje kanabinoidom thc kao dodatnom aktivnom tvari

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20231591TT HRP20231591T1 (hr) 2017-07-11 2018-07-11 Solubilizat s kurkuminom i barem jednom drugom aktivnom tvari

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20231135TT HRP20231135T1 (hr) 2017-07-11 2019-07-10 Solubilizat s kurkuminom i najmanje kanabinoidom thc kao dodatnom aktivnom tvari

Country Status (19)

Country Link
US (8) US11344509B2 (hr)
EP (2) EP3651804B1 (hr)
JP (1) JP2020529974A (hr)
KR (1) KR20200029002A (hr)
CN (2) CN111201041A (hr)
BR (1) BR112020000398A2 (hr)
CA (2) CA3148455A1 (hr)
DK (3) DK3651804T5 (hr)
ES (3) ES2965739T3 (hr)
FI (2) FI3651804T3 (hr)
HR (3) HRP20231591T1 (hr)
HU (4) HUE064518T2 (hr)
MX (2) MX2021000339A (hr)
PL (3) PL3651805T3 (hr)
PT (2) PT3651804T (hr)
RS (3) RS64650B1 (hr)
RU (2) RU2752078C1 (hr)
UA (1) UA125552C2 (hr)
WO (3) WO2019011954A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000398A2 (pt) 2017-07-11 2020-07-14 Aquanova Ag solubilizado com curcumina e, opcionalmente, pelo menos umas outras substâncias ativas
PL3820527T3 (pl) 2018-07-11 2024-01-03 Aquanova Ag Solubilizator ksantohumolu
DE202019104734U1 (de) * 2019-08-29 2020-12-01 Aquanova Ag Folsäure-Solubilisat
WO2023282783A1 (ru) * 2021-07-09 2023-01-12 Акционерное Общество "Акванова Рус" Мицеллированный раствор активного компонента на основе экстракта лакрицы, способ его получения и применения
WO2023224134A1 (ko) * 2022-05-16 2023-11-23 주식회사 다미래 수용화 커큐민과 보스웰리아 추출물을 이용한 인지 능력 개선용 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07165588A (ja) 1993-12-13 1995-06-27 Tsumura & Co 脳機能改善剤
US5744161A (en) 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
US5629351A (en) 1995-04-13 1997-05-13 Council Of Scientific & Industrial Research Boswellic acid compositions and preparation thereof
EP1358876B1 (de) 2002-04-30 2007-11-07 Cognis IP Management GmbH Mikrokapseln mit Anti-Aknewirkstoffen
ES2258200T3 (es) * 2002-12-18 2006-08-16 Dohler Gmbh Bebida que contiene xantohumol.
WO2005092352A1 (fr) 2004-03-26 2005-10-06 Jianzhong Zhu Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques
US20080220102A1 (en) 2005-07-08 2008-09-11 Dariush Behnam Solubilsation Products of an Active Ingredient Extract
DE102006024911A1 (de) 2006-05-24 2007-11-29 Aquanova Ag Boswellinsäure-Konzentrat
DK1903866T3 (en) 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
WO2007058480A1 (en) 2005-11-16 2007-05-24 Md Bioalpha Co., Ltd. Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin
TW200806306A (en) 2006-02-24 2008-02-01 Kaneka Corp Oil-in-water emulsion composition containing licorice-derived polyphenol
TW200808333A (en) 2006-04-17 2008-02-16 Kaneka Corp Licorice polyphenol preparation
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
DE102006062264A1 (de) 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
US9241893B2 (en) 2007-11-19 2016-01-26 Stiefel Laboratories, Inc. Topical cosmetic skin lightening compositions and methods of use thereof
WO2009126320A1 (en) 2008-04-11 2009-10-15 Betal, Llc Xanthohumol compositions and methods for treating skin diseases or disorders
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2192160B1 (de) 2008-12-01 2016-08-17 Aquanova Ag Micellar integrierter Oxidationsschutz für natürliche Farbstoffe
US20110086017A1 (en) 2009-10-08 2011-04-14 Svetlana Kravets Medical Food composition and methods for management of inflammatory processes in mammals
CN103298443B (zh) 2011-01-06 2015-06-17 花王株式会社 水包油型乳化组合物
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
DE202012012130U1 (de) * 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
US10213391B2 (en) 2014-05-06 2019-02-26 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160008298A1 (en) 2014-07-14 2016-01-14 Oregon State University Xanthohumol-based compounds and compositions thereof, and methods of making and using the same
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US20160081975A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Soft gel compositions and pre-gel concentrates
US20170333515A1 (en) * 2015-11-10 2017-11-23 Eric H. Kuhrts Compositions and methods for enhancing the metabolic activity or stability of curcumin
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
CN106619588B (zh) * 2016-12-29 2019-08-16 厦门金达威生物科技有限公司 一种含辅酶q10的自微乳型营养组合物、制备方法及用途
GB2559774B (en) * 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
WO2019011415A1 (de) 2017-07-11 2019-01-17 Aquanova Ag SOLUBILISAT MIT CURCUMIN, XANTHOHUMOL UND SÜßHOLZWURZELEXTRAKT
BR112020000398A2 (pt) 2017-07-11 2020-07-14 Aquanova Ag solubilizado com curcumina e, opcionalmente, pelo menos umas outras substâncias ativas

Also Published As

Publication number Publication date
HUE064518T2 (hu) 2024-03-28
MX2021000339A (es) 2021-03-25
WO2019011955A2 (de) 2019-01-17
PT3651804T (pt) 2023-10-18
DK3651805T3 (da) 2023-12-11
EP3651805A2 (de) 2020-05-20
EP3651805B1 (de) 2023-10-25
WO2019011990A1 (de) 2019-01-17
DK3651804T5 (da) 2023-10-09
CN111163806A (zh) 2020-05-15
CA3069621A1 (en) 2019-01-17
FI3820528T3 (en) 2023-10-17
KR20200029002A (ko) 2020-03-17
RS64636B1 (sr) 2023-10-31
PT3651805T (pt) 2023-12-22
US20220249400A1 (en) 2022-08-11
US20220133682A1 (en) 2022-05-05
US20220125741A1 (en) 2022-04-28
WO2019011955A3 (de) 2019-05-16
ES2965739T3 (es) 2024-04-16
WO2019011954A1 (de) 2019-01-17
HUE063768T2 (hu) 2024-02-28
MX2021000385A (es) 2021-03-25
DK3651804T3 (da) 2023-09-25
RS64650B1 (sr) 2023-10-31
BR112020000398A2 (pt) 2020-07-14
US11931322B2 (en) 2024-03-19
DK3820528T3 (da) 2023-10-16
ES2960689T3 (es) 2024-03-06
FI3651804T3 (en) 2023-10-04
CN111201041A (zh) 2020-05-26
HRP20231135T1 (hr) 2024-01-05
JP2020529974A (ja) 2020-10-15
US20240325318A1 (en) 2024-10-03
EP3651804B1 (de) 2023-08-23
PL3651805T3 (pl) 2024-04-08
EP3651804A1 (de) 2020-05-20
CA3148455A1 (en) 2019-01-17
ES2960296T3 (es) 2024-03-04
PL3651804T3 (pl) 2024-01-03
RU2752078C1 (ru) 2021-07-22
RU2771527C1 (ru) 2022-05-05
US20240216297A1 (en) 2024-07-04
CA3069621C (en) 2022-05-03
US11197834B2 (en) 2021-12-14
US20200222346A1 (en) 2020-07-16
HUE063382T2 (hu) 2024-01-28
US20200129452A1 (en) 2020-04-30
US11344509B2 (en) 2022-05-31
US20220133646A1 (en) 2022-05-05
HUE063380T2 (hu) 2024-01-28
PL3820529T3 (pl) 2024-01-03
UA125552C2 (uk) 2022-04-13
HRP20231591T1 (hr) 2024-03-15
RS64642B1 (sr) 2023-10-31

Similar Documents

Publication Publication Date Title
HRP20231160T1 (hr) Solubilizat s kurkuminom, bosvelijom i ksantohumolom
José Bagur et al. Saffron: An old medicinal plant and a potential novel functional food
Zhao et al. Extraction of a soluble polysaccharide from Auricularia polytricha and evaluation of its anti-hypercholesterolemic effect in rats
Dong et al. Targeting the interplay of autophagy and ROS for cancer therapy: An updated overview on phytochemicals
CA2608651A1 (en) Compositions and methods for the prevention and treatment of conditions associated with inflammation
Morbidelli et al. Use of nutraceuticals in angiogenesis-dependent disorders
HRP20231263T1 (hr) Solubilizat koji sadrži kurkumin i barem jedan kanabinoid kao dodatnu aktivnu tvar
US20210275485A1 (en) Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
WO2008059965A1 (fr) Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux
Ullah et al. Beneficial effects of plant extracts and bioactive food components in childhood supplementation
EP3762006B1 (en) Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
Park et al. Immunomodulatory effects of Curcuma longa L. and Carthamus tinctorius L. on RAW 264.7 macrophages and cyclophosphamide-induced immunosuppression C57BL/6 mouse models
EP2716167A1 (en) Non-pharmaceutical composition comprising short chain fatty acids
DK2705761T3 (en) NUTRITIONAL COMPOSITION FOR GRAVID WOMEN
Rajalakshmi et al. Advantages and Disadvantages of Nutraceuticals
Kim et al. Alternative therapy trends among Korean postmenopausal women
Bathaie Saffron as a functional food and a nutraceutical using saffron and its constituents as the nutraceutics to protect against chronic diseases
Yap Reversing breast cancer in a premenopausal woman: A case for phyto-nutritional therapy
Ahmed et al. Study the effect of Ginger (Zingiber officinale) on weight loss and lipid profile on obese rats
KR102573152B1 (ko) 커큐민 및 선택적으로 적어도 1종의 다른 활성 물질을 갖는 가용화물
Gohil Nutraceuticals: A Holistic Approach to Health
Pandey et al. Identification of Bioactive Phytoconstituents and Biological Activities of Wheat Germ Oil: A Critical Review
Agrawal et al. Translational Research and Clinical Advancements with Nutraceutical Supplements
Onaolapo et al. Nutraceuticals as Therapeutic Agents
Chakraborty Bioactive compounds and nutraceuticals from seaweeds